Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Moodys
Baxter
McKesson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pirarubicin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Pirarubicin: Patents, clinical trial progress, indications

Pirarubicin is an investigational drug.

There have been 18 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Beijing Jishuitan Hospital, Peking University First Hospital, and Peking University People's Hospital.

There are two US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Pirarubicin
TitleSponsorPhase
Combination Therapy of Anthracyclines for Children With NephroblastomaShengjing HospitalPhase 4
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaBeijing Jishuitan HospitalPhase 2/Phase 3
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaChinese PLA General HospitalPhase 2/Phase 3

See all Pirarubicin clinical trials

Clinical Trial Summary for Pirarubicin

Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin

See all Pirarubicin clinical trials

US Patents for Pirarubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pirarubicin   See Pricing Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   See Pricing
Pirarubicin   See Pricing Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   See Pricing
Pirarubicin   See Pricing Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pirarubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Pirarubicin World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   See Pricing
Pirarubicin Australia 2006269422 2025-07-07   See Pricing
Pirarubicin Canada 2614436 2025-07-07   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.